This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Breastfeeding and beta blockers

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Breastfeeding and beta blockers

  • labetalol, metoprolol, and propranolol are the beta-blockers of choice during breastfeeding (1)
    • very small amounts get into breast milk, and they have shorter half-lives leading to a lower risk of accumulation in a breastfed infant. Labetalol and metoprolol also do not rely on excretion in the urine, again leading to less risk of accumulation
    • amount of beta-blockers found in breastmilk varies depending on the exact medication (2)
      • atenolol, acebutolol, and nadolol are present in high amounts in breast milk and may not be recommended while breastfeeding
      • propranolol, labetalol, and metoprolol have been found in small amounts in breastmilk and are considered compatible with breastfeeding.
    • labetalol and propranolol are used therapeutically in neonates, and metoprolol in infants from one month of age
      • however, any beta-blocker may be used during breastfeeding if clinically appropriate, although more careful monitoring may be required
    • labetalol
      • infant monitoring whilst using labetalol whilst breastfeeding (1)
        • as a precaution, monitor infants for signs of bradycardia or hypoglycaemia including drowsiness, lethargy, and poor feeding and inadequate weight gain
        • hypoglycaemia may also manifest as jitteriness/ tremors, sweating, irritability, fast breathing, looking pale, and unusual cry
        • notes on labetalol
          • limited evidence indicates that levels in breast milk are generally very small
            • most breastfed infants are likely to get less than 1% of maternal weight-adjusted dose via breast milk
          • labetalol is mostly metabolised in the liver, and its half-life in adults is 6-8 hours
            • risk of accumulation in a breastfed infant is therefore low
          • most studies have not reported any adverse effects in breastfed infants
            • one premature infant developed sinus bradycardia when exposed to labetalol via breast milk, suggesting additional caution is needed in very young or premature infants
    • metoprolol
      • infant monitoring whilst using metoprolol whilst breastfeeding (1)
        • as a precaution, monitor infants for signs of bradycardia or hypoglycaemia including drowsiness, lethargy, and poor feeding and inadequate weight gain
        • hypoglycaemia may also manifest as jitteriness/tremors, sweating, irritability, fast breathing, looking pale, and unusual cry
        • notes on metoprolol
          • limited evidence indicates that amounts in breast milk are generally very small
            • most breastfed infants are likely to get less than 2% of the weight-adjusted maternal dose of metoprolol via breast milk
          • metoprolol is mostly metabolised in the liver, and its half-life in most adults is 3-7 hours, and 5-10 hours in neonates
            • note though that, metoprolol is metabolised by the hepatic cytochrome P450 2D6 enzyme
              • some individuals do not have effective levels of this enzyme ("poor metabolisers"), resulting in slower metabolism and a half-life of 7-9 hours in adults, and presumably longer in neonates
              • s may increase the risk of infant side effects
              • risk of significant accumulation in a breastfed infant is therefore relatively low, but not impossible, especially in very young infants
    • propranolol
      • infant monitoring whilst using propranolol whilst breastfeeding (1)
        • as a precaution, monitor infants for signs of bradycardia or hypoglycaemia including drowsiness, lethargy, and poor feeding and inadequate weight gain
        • hypoglycaemia may also manifest as jitteriness/tremors, sweating, irritability, fast breathing, looking pale, and unusual cry
        • notes on propranolol
          • limited evidence indicates the amounts in breast milk are very small
            • most breastfed infants are likely to get less than 1% of the weight-adjusted maternal daily dose of propranolol via breast milk
            • despite propranolol almost being completely excreted in the urine, it is highly lipid soluble and highly protein bound, and has a half-life of 3-6 hours
              • accumulation in a breastfed infant is therefore unlikely
          • have been no reported side effects in infants clearly attributed to exposure to propranolol via breast milk
          • is used therapeutically in infants from birth

  • Effect on breastfeeding
    • beta-blockers are not known to have an effect on breastfeeding (1)
      • however, non-selective beta-blockers (especially labetalol) have been reported to cause nipple pain or Raynaud’s phenomenon of the nipple

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.